α-Mangostin Treats Early-Stage Adjuvant-Induced Arthritis of Rat by Regulating the CAP-SIRT1 Pathway in Macrophages.

BACKGROUND: Studies have found that α-mangostin (MG) can relieve experimental arthritis by activating cholinergic anti-inflammatory pathway (CAP). It affects the polarization of macrophages and the balance of related immune cell subpopulations, but the specific mechanism is still unclear. It has been found that silent information regulator 1 (SIRT1) is closely related to macrophage activity. The purpose of this study is to explore the mechanism of MG intervening in macrophage polarization during treatment of early adjuvant-induced (AIA) rats through the CAP-SIRT1 pathway.
METHODS: We investigated the polarization of M1 macrophages and the differentiation of Th1 in AIA rats by flow cytometry. Activity of acetylcholinesterase (AChE) and the level of nicotinic adenine dinucleotide (NAD+) in serum were also detected, and immunohistochemical was used to detect the levels of α7 nicotinic cholinergic receptor (α7nAChR) and SIRT1. Then in macrophages, the molecular mechanism of MG regulating the abnormal activation of macrophages in rats with early AIA through the CAP-SIRT1 pathway was studied.
RESULTS: MG can significantly inhibit the polarization of M1 macrophages and the differentiation of Th1 in AIA rats in the acute phase of inflammation. MG can significantly inhibit the activity of AChE and increase the level of NAD+, thereby further up-regulated the expression levels of α7nAChR and SIRT1. Meanwhile, MG inhibited nuclear factor-κB (NF-κB)-mediated inflammation by activating the CAP-SIRT1 pathway in macrophages.
CONCLUSION: In summary, the stimulation of MG induced CAP activation, which up-regulated SIRT1 signal, and thereby inhibited M1 polarization through the NF-κB pathway, and improved the pathological immune environment of early-stage AIA rats.

Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease with high disability rate, which seriously affects the labor ability and quality of life of patients.1 More and more evidences show that the development of RA is the result of immune cells abnormalities.2 The phenomenon that a large number of macrophages infiltrated in the synovium of RA patients is regarded as an important sign of early RA, and their number is closely related to disease activity.3 At present, it is generally believed that 1–2 months in the initial stage of RA is the “window period” of treatment, and effective response will significantly improve the prognosis.4,5 According to this consensus, biological therapies targeting cytokines involved in macrophage-related immune responses, such as interleukin 1β (IL-1β) and tumor necrosis factor-α (TNF-α), have been applied successfully to RA treatments. However, it is difficult to restore the overall balance of the complex cytokine network with one single or a few targeted drugs in combination therapy, and the high price is also an important factor restricting its application.6

In recent years, great progress has been made in understanding the association of cholinergic systems with immunity and inflammation. Cholinergic anti-inflammatory pathway (CAP) is an important functional branch of cholinergic nerve discovered in recent years. The basic molecular mechanism of CAP activation is based on the stimulation of α7 nicotinic cholinergic receptor (α7nAChR) by acetylcholine (ACh) regulated and released by autonomic nerves.7,8 Recent studies have shown that CAP stimulation has great potential in the treatment of inflammatory diseases. Electrical stimulation of the vagus nerve or stimulation with α7nAChR selective agonists can effectively alleviate the clinical symptoms of RA and corresponding animal models.9–11 Silent information regulator 1 (SIRT1), a third type of histone deacetylase dependent on nicotine adenine dinucleotide (NAD+), as an important regulatory center of energy metabolism,12 is theoretically affected by CAP. In view of the far-reaching effects of CAP on immunity and inflammation, anti-rheumatic therapy targeting CAP has a bright future, although there is currently no such drug. Identifying CAP agonists from traditional drugs or natural products is a feasible way to achieve a breakthrough in RA treatment.

Our previous research found that xanthone derivatives (XANs) can restore the cytokine composition in arthritis model animals, reduce the level of oxidative stress, and inhibit the abnormal proliferation of FLS.13,14 Among investigated compounds, α-mangostin (MG, an isoprenyl-substituted xanthone isolated from mangosteen) exhibits particularly significant anti-rheumatic effects.15,16 We also found that MG induced the excitement of cholinergic nerves in rats by promoting the expression of α7nAChR, thereby reducing the severity of acute lung injury caused by LPS.17 Further studies have shown that the up-regulation of CAP of peripheral monocytes by MG can improve the systemic immune environment, restore the Th17/Treg ratio, and reduce the release of pro-inflammatory factors, exerting a therapeutic effect on arthritic rats.18 In addition, our recent research has found that MG can effectively inhibit the body’s energy metabolism, which is prominently manifested as a down-regulation of nicotinamide phosphoribosyltransferase (NAMPT)/NAD. Based on the widely recognized energy-immune feedback mechanism, this phenomenon has far-reaching significance for the treatment of RA and other immune-related diseases. As an NAD+-dependent enzyme, SIRT1 must also be affected by MG stimulation during this process.

Macrophages, as the main body of the innate immune system, will inevitably induce lymphocyte imbalance in their functional state, thereby promoting the development of secondary symptoms.19 Therefore, the effect of MG on the immune function of RA patients by regulating macrophages through CAP-SIRT1 is of great significance. In this study, we further verified the stimulating effect of MG on the CAP-SIRT1 pathway in macrophages, and preliminarily clarified its correlation with the therapeutic effect of AIA in rats.

Materials and Methods

Materials and Reagents

MG (purity >98%) was purchased from SanHerb Bioscience (Chengdu, Sichuan, China). Carboxyl methyl cellulose sodium (CMC-Na) was obtained from Aladdin (Shanghai, China). Lipopolysaccharide (LPS, from the Gram-negative bacterium E. coli 055:B5) and methyllycaconitine (MLA, α7nAChR specific inhibitor) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Roswell Park Memorial Institute (RPMI) 1640 medium and Dulbecco’s modified Eagle’s medium (DMEM) were bought from Hyclone (Logan City, UT, USA). Fetal bovine serum (FBS) was purchased from Gibco (CA, USA). Lymphocyte separation solution was bought from Solarbio (Beijing, China). Anti-rat CD4-PE, IFN-γ-FITC, CD86-FITC and CD11b-PE antibodies were purchased from BioLegend (San Diego, CA, USA). Anti-rat p65, ac-p65, p-p65, α7nAChR and SIRT1 antibodies were the products of Affinity Biosciences (Changzhou, Jiangsu, China). Biotin-conjugated secondary antibodies were supplied by Beyotime Biotech (Nantong, Jiangsu, China). Acetylcholinesterase (AChE) assay kit and Coenzyme I NAD (H) assay kit were supplied by JianCheng Bioengineering Institute (Nanjing, Jiangsu, China).

Cells and Animals

RAW264.7 cells were purchased from American Type Culture Collection (ATCC number: TIB-71, USA). Male Sprague–Dawley (SD) rats (180±20g) were bought from Qinglongshan Experimental Animal Company (Nanjing, Jiangsu, China). The animals were acclimated for 7 days prior to experimental procedures. The animal experimental protocols were approved by the Ethical Committee of The Second Affiliated Hospital of Wannan Medical College (no. wyefy 2018-004), strictly in accordance with the Guidelines for the Care and Use of Laboratory Animals (United States National Research Council, 2011).

Induction of Adjuvant-Induced (AIA) in Rats and Treatments

Bovine type II collagen (Chondrex, Redmond, WA, USA) for immunization was dissolved in 0.1M acetic acid, stirred at 4°C and fully dissolved to prepare a solution with a concentration of 2 g/L. The solution was then mixed into complete Freund’s adjuvant (CFA) dropwise, and fully emulsified in an ice-water bath to obtain a milky homogeneous emulsion. The emulsion was used to implement multiple intradermal injections (0.2 mL) on the back and tail roots of SD rats, which was recorded as the 0d, and the 7d was used to enhance immunity. After the first injection, 18 immunized rats were randomly divided into AIA group, MG early treatment group (0–20d) and MG late treatment group (21–40d). Another 6 healthy rats were taken as normal control group. MG was dissolved in 0.5% CMC-Na with the help of ethanol and Tween 40, and was administered to rats by gavage at a dose of 40 mg/kg per day. The normal and AIA groups were treated simultaneously with the same amount of 0.5% CMC-Na.15

Histopathological and Immunohistochemical Evaluation

The rats were sacrificed on day 45 then the hind ankle joints and spleen were fixed in 4% formaldehyde solution. After 14 days of decalcification treatment, the joint tissues were transparentized. Then the specimens were embedded in paraffin, sectioned and stained with hematoxylin–eosin (HE). The pathological changes of the joints and spleen were observed under a light microscope and scored with the same criteria defined previously.20–22

We dewaxed the paraffin sections and immersed them in a methanol solution of H2O2 to inactivate endogenous peroxidase. The slices were heated by microwave and repaired by citric acid, then incubated with corresponding primary and secondary antibodies in sequence. The signal was then visualized by diaminobenzidine (DAB) chromogenic solution and hematoxylin (Zsbio, Beijing, China). Stained sections were finally dehydrated, sealed, and observed under a light microscope.22

Cell Harvest and Culture

Macrophages were obtained from the abdominal cavity of each group of rats. 10 mL of serum-free DMEM were injected into the abdominal cavity of rats, and the abdomen was massaged for 2–3 minutes and then left for 5 minutes to enrich the macrophages. Then, we aspirated the cell suspension, centrifuged at 2500 rpm for 10 minutes, and added 10% high sugar DMEM to resuspend it in a six-well plate. After the cells had been cultured for 2 h, we discarded the supernatant and washed three times with sterile PBS. The attached macrophages are purified macrophages.23

The peripheral blood mononuclear cells (PBMCs) of each group of rats were prepared according to the following steps. Fresh blood was diluted with pre-cooled RPMI1640, then added to a 15mL centrifuge tube. We mixed the diluted blood with an equal volume of peripheral blood lymphocyte separation solution. The diluted blood was slowly spread on the upper layer of the separation solution, and the PBMCs were separated from the whole blood by gradient centrifugation.18

In addition, RAW264.7 cells were cultured in a six-well plate with a density of 2×105/well, and DMEM medium containing 20% FBS was adopted in the culture system.

After different stimuli, cells can be divided into control, LPS (2 nM), MLA (5 nM), MG (5 μg/mL) and MLA+MG. After the cells were cultured for 24h, the supernatant was discarded and the cells were washed twice with pre-cooled PBS. The cells were centrifuged at 12,000 rpm at 4°C for 10 minutes, and the supernatant was taken as the protein sample for the next experiment.

Evaluation of Activity of AChE and Level of NAD+ in Serum Under MG Treatments

Before the test, serum was obtained from the whole blood of each group of rats by centrifugation. The activity of AChE in serum was directly detected by AChE assay kit. The absorbance of the tested sample was read at 412 nm, and the read was used for the calculation of AChE activity according to the quantitative formula given in the manual.

Extraction of NAD+ in serum: serum was mixed proportionally with the acidic extract in the kit, boiled for 5 minutes, cooled in an ice bath, and centrifuged at 10000g for 10 minutes at 4°C. The supernatant was transferred to another new centrifuge tube, and an equal volume of alkaline extract was added and mixed. The supernatant was centrifuged at 10000g at 4°C for 10 min, and the supernatant was taken for detection. The absorbance of the tested sample was read at 570 nm, and the read was used for the calculation of NAD+ activity according to the quantitative formula given in the manual.

Western Blot Assay

Qualified protein samples (10 μg/well, based on the BCA test) were subjected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). Separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane, which were then incubated with primary antibodies (p65 anti-rabbit, 1:1000; p-p65 anti-rabbit, 1:1000; ac-p65 anti-rabbit, 1:1000; SIRT1 anti-rabbit, 1:1000; α7nAChR anti-rabbit, 1:1000; β-actin anti-rat, 1:3000) overnight at 4°C, followed by blocking with 5% skim milk for 2 h at room temperature. Followed by incubation with a specific antigen-labeled secondary antibody. Finally, signals were developed with an enhanced chemiluminescence (ECL) substrate kit. The results were photographed and analyzed using ImageJ software.

Flow Cytometry

The macrophages of rats in each group were obtained according to the above method. CD11b antibodies were added to cells and protected from light for 30 minutes. After cells were fixed and membrane permeabilized, different fluorescently labeled CD86 antibodies were added and incubated for 1 hour at room temperature. Treated cells were washed with PBS and centrifuged at 2500 rpm/10 min. The supernatant was removed and resuspended in PBS. Similarly, PBMC was obtained according to the above method. Surface antibodies CD4 were added, and the membrane was fixed and permeabilized. Different fluorescein-labeled IFN-γ antibodies were added and incubated for 30 min in the dark, washed and resuspended. The stained cells were subsequently fed to a flow cytometer (FC500, Beckman) for quantitative analysis. Obtained data were analyzed by FlowJo (version 10). CD11b+CD86+ and CD4+IFN-γ+ cells were identified as M1 and Th1 cells, respectively.

Data Analysis

The data were typically expressed as mean ± standard deviation (SD) (). Data distribution was evaluated by Shapiro–Wilk test and P-P plot (), then statistical differences among different groups were evaluated using one-way analysis of variance followed by the Tukey post hoc tests using the SPSS 16.0 software. The Kruskal–Wallis H-test followed by the Dunn’s test was used for skewed data. The skewed data were presented as median (min - max) (). Differences were considered statistically significant when P<0.05. All the statistical analyses were performed with GraphPad Prism 8.0 (Cary, NC, USA).

Results

The Effect of MG Periodic Treatment on the Severity of Inflammation in AIA Rats

As shown in Figure 1A, hind paws of AIA rats suffered from severe inflammation, which was not obvious in MG (early) and MG (late) treated rats. Comparatively, arthritic condition of MG (late)-treated rats was worse than MG (early) counterparts, as joints deformation and bulbous inflammation can be still noticed in their paws. This provided basic evidence for the anti-rheumatic properties of MG in vivo.

Figure 1

Therapeutic effects of MG on AIA rats. (A) Morphological observation of hind paw (B) histological examination of joint; (C) histological examination of spleen; (D) histopathological scores of joint and spleen. *P<0.05 and **P<0.01 compared with AIA rats.

In the histological examination, compared with normal rats, AIA rats showed excessive proliferation of joint synovial cells, massive infiltration of inflammatory cells, pannus formation and articular cartilage erosion. MG ameliorated all the pathological changes effectively (Figure 1B and D). In addition, there were abnormal changes in the spleen of AIA rats, including the blurring of the white pulp and the red pulp, and the hyperplasia of the white pulp. At the same time, the increased density of lymphocytes around the germinal center artery and the obvious hyperplasia of the red pulp can be seen. After treatment with MG, the number of germinal centers was significantly reduced and the boundary between white and red pulp was significantly improved (Figure 1C and D). The above facts show that MG treatment can reduce the pathological score, and thereby improved the pathological manifestations. And the therapeutic effect of MG (early) is slightly better than MG (late).

MG Inhibited Polarization of M1 Macrophages in AIA Rats

The phenomenon that a large number of macrophages infiltrated in the synovium is regarded as important signs of the early stage of RA, and their number is closely related to the disease activity. Macrophages as the main composition of the innate immune system, their functional state disorder will inevitably induce lymphocyte imbalance, and thereby promote the development of secondary symptoms.5 Because the increase of M1 macrophages and Th1 cells plays an important role in the occurrence and development of RA.24,25 In this study, we used flow cytometry to investigate the effects of MG on macrophage polarization and peripheral T lymphocyte differentiation during the acute and secondary inflammation in AIA rats. As anticipated, M1 macrophages were increased significantly in the AIA rats. Both the MG (early) and the MG (late) significantly reduced its distribution, from 22.20% to 9.51% and 11.50%, respectively, and MG (early) has a stronger effect on inhibiting M1 polarization (Figure 2A and C). Accordingly, compared with normal rats, Th1 subset in AIA rats was increased significantly. Both the MG (early) and the MG (late) significantly reduced its distribution, from 29.20% to 8.44% and 11.80%, respectively, and MG (early) has a stronger effect on inhibiting Th1 differentiation (Figure 2B and D). The above clues preliminarily suggest that MG has a significant inhibitory effect on M1 polarization in the acute phase of inflammation in AIA rats. This property is meaningful for subsequent inflammation alleviation and immune homeostasis restoration.

Figure 2

Effects of MG on the polarization of M1 macrophages and Th1 distribution of PBMCs in AIA rats were explored by flow cytometry. (A) Representative raw data indicating the polarization of M1 macrophages; (B) representative raw data indicating the Th1 distribution; (C and D) quantification results of flow cytometry experiments. ##P<0.01 compared with normal, *P<0.05, **P<0.01 compared with AIA rats, &P<0.05 compared with MG (early).

MG Activated the CAP-SIRT1 Pathway in Macrophages

Our previous study found that MG can induce the activation of CAP in vivo and in vitro, and the selective CAP can partially reverse the anti-inflammatory effect of MG (data not provided). At the same time, we also found that MG can effectively inhibit the body’s energy metabolism, which is prominently manifested by down-regulation of NAMPT/NAD.7 Vagus nerve activation and up-regulation of CAP are orchestrated in energy metabolism. SIRT1 is regarded as the core node of the cross-talk between energy metabolism and immune inflammation, which must be affected by the state of CAP in theory. Therefore, we simultaneously analyzed the status of the CAP-SIRT1 pathway to further clarify the molecular mechanism of MG intervention in macrophage polarization during treatment of the acute inflammation of AIA.

The results show that α7nAChR was mainly expressed on lymphocytes located in the medullary part of the spleen (Figure 3A). After MG treatment, this decline in the acute inflammation phase was effectively restored, which was especially notable during acute inflammation (Figure 3C). This result demonstrates the positive effects of MG on the CAP in the immune system in vivo. Similarly, SIRT1 is also mainly distributed in the medulla of the spleen (Figure 3B) and significantly reduced in AIA rats. MG treatment reversed this abnormality (Figure 3D). The decrease in α7nAChR and SIRT1 in AIA rats was accompanied by a significant increase in AChE activity and a decrease in NAD+ levels. It seems that MG has a regulatory effect on CAP-SIRT1, because the above abnormal changes have recovered to varying degrees after MG treatment (Figure 3E and F).

Figure 3

Possible effects of MG on CAP-SIRT1 in AIA rats. (A) Local expression of α7nAChR in the spleen; (B) local expression of SIRT1 in the spleen; (C and D) quantification results of the immunohistochemical experiment analyzed by ipwin software; (E) inhibitory effect of MG on enzymatic activity of AChE in serum; (F) MG increases the concentration of NAD+ in the serum. #P<0.05, ##P<0.01 compared with normal rats, *P<0.05, **P<0.01 compared with AIA rats, &P<0.05 compared with MG (early).

Based on the above results, we speculated that MG may stimulate α7nAChR to activate CAP, and then further up-regulate SIRT1 signal, which will improve the immune environment in the acute inflammation phase of AIA. Therefore, we isolated macrophages from each group of rats for further verification. The result echoes the result of spleen immunohistochemistry. Compared with normal, the expression of α7nAChR and SIRT1 in macrophages of AIA rats was significantly decreased (Figure 4A). MG can reverse the low expression of α7nAChR and SIRT1 in AIA rats (Figure 4B and C). Since the overactivation of nuclear factor-κB (NF-κB) is closely related to the polarization of macrophages, its changes are essential to alleviate the joint inflammation of AIA/RA. As expected, MG treatment inhibited the phosphorylation of p65 in macrophages of AIA rats (Figure 4A and D). In addition, SIRT1 is a deacetylase deacetylating a variety of substrates. We also investigated the deacetylation effect of SIRT1 on p65. Compared with AIA rats, the high expression of SIRT1 induced by MG is accompanied by enhanced deacetylation of p65 (Figure 4A and E). Based on the above clues, we believe that MG may act on the abnormal polarization of M1 macrophages in the acute inflammation phase of AIA through the CAP-SIRT1 pathway, and affect the development and prognosis of the disease.

Figure 4

Effect of MG activated CAP-SIRT1 pathway on NF-κB-mediated inflammatory response in rat macrophages. (A) Expression of α7nAChR, SIRT1, ac-p65, p-p65 and p65 in macrophages investigated by immunoblotting; (B–E) quantitative result of (A). #P<0.05, ##P<0.01, ###P<0.001 compared with normal, *P<0.05, **P<0.01, ***P<0.001 compared with AIA rats, &P<0.05 compared with MG (early).

MG Relieved LPS-Induced Inflammation by Regulating α7nAChR in RAW264.7 Cells to Stimulate SIRT1

Based on the above results, in order to further explore the regulatory effect of CAP on SIRT1 under inflammatory conditions, we used MLA to selectively inhibit α7nAChR and then antagonize CAP. The results show that compared to control, LPS can significantly inhibit the expression of α7nAChR and SIRT1 (Figure 5A). Similarly, MLA can significantly inhibit the expression of α7nAChR (Figure 5A and B), and the expression of SIRT1 is also down-regulated accordingly (Figure 5A and C). Compared with LPS, MG can up-regulate the expression levels of α7nAChR and SIRT1. Importantly, MG can also reverse the down-regulation of α7nAChR and SIRT1 levels caused by MLA (Figure 5). Therefore, we can preliminarily conclude that MG stimulates the expression of SIRT1 at least partially through α7nAChR activation.

Figure 5

MG relieves LPS-induced inflammation by regulating α7nAChR in RAW264.7 cells to stimulate SIRT1. (A) Expression of α7nAChR, SIRT1 in RAW264.7 cells investigated by immunoblotting; (B and C) quantitative result of (A). ##P<0.01 compared with control, *P<0.05, **P<0.01 compared with LPS, &P<0.05, &&P<0.01 compared with MLA.

Discussion

MG is a natural polyphenol, mainly distributed in the peel of mangosteen. Due to its remarkable biological activity and high abundance, the exploration of its medicinal potential is not only clinically significant, but also economically important.26 Previous studies have shown that MG and its extract have remarkable effects on experimental arthritis model rats.15,16 In addition to the improvement of arthritis indicators, the above treatments have a profound impact on the immune microenvironment. For example, the expression of Toll-like receptors 4 (TLR4) and p-p65 in joints is greatly reduced, and as well as the distribution of Th1 cells. TLR4/NF-κB activation is a key event in the polarization of M1 macrophages. The above clues preliminarily suggest that MG has an inhibitory effect on M1 polarization under active RA conditions. Although it is generally believed that the pathological changes of RA are mainly controlled by lymphocytes, especially CD4+ T cells. But the role of macrophages in RA cannot be ignored. As an indispensable part of innate immunity, these cells first sense pathogens and transmit signals to the adaptive immune system. In addition, M1 polarization is closely related to the manifestations of arthritis, including persistent inflammation and progressive tissue injury of joints. The imbalance of macrophage polarization may be the main reason for the deterioration of immune environment in RA patients. M1 macrophages are the main promoting factor of Th1 differentiation. From this perspective, the effects of MG on M1 polarization and Th1 differentiation in AIA rats revealed by this study are very meaningful and enlightening.

Our early research shows that this phenomenon is closely related to CAP activation. Electrical stimulation of the vagus nerve or stimulation with α7nAChR selective agonists can effectively alleviate the clinical symptoms of RA and corresponding animal models. CAP activation is accompanied by a significant increase in M2 polarization and a decrease in M1 polarization.9 Macrophages are the main immune cells highly expressing α7nAChR in the periphery. Further studies have shown that the up-regulation of CAP of peripheral monocytes by MG can improve the systemic immune environment, restore the Th17/Treg ratio, and reduce the release of pro-inflammatory factors, demonstrating a therapeutic effect on CIA rats.18 Therefore, the activation of CAP by MG in RA is beneficial to suppress the abnormal polarization of M1 macrophages. In order to verify the above speculation, it is imperative to clarify the effect of MG on CAP in the immune system. On the one hand, MG treatment greatly inhibits the catalytic activity of AChE, and the impaired hydrolysis will eventually lead to slowed clearance of ACh, due to the prolonged CAP activation, it will elicit anti-inflammatory effects. On the other hand, we found that MG can effectively inhibit the body’s energy metabolism, which is prominently manifested by down-regulation of NAMPT/NAD. Based on the widely recognized energy-immune feedback mechanism, this phenomenon has far-reaching significance for the treatment of RA and other immune-related diseases. As an NAD+-dependent enzyme, the function of SIRT1 must be affected by MG stimulation during this process. It is puzzling that previous reports and our research have found that SIRT1 is highly expressed under RA/CIA conditions, and MG negatively regulates SIRT1 in this state. Considering the spontaneous recovery of M2 macrophages development is common in RA patients at remission stages, we believe that the increased expression of SIRT1 in the late stage of RA/CIA is a part of self-balancing immune mechanism. MG may accelerate the pre-disease SIRT1-dependent M2 polarization process, thereby weakening the demand for spontaneous SIRT1 upregulation.

As mentioned above, CAP activation inhibits M1 polarization. It is worth noting that this process is accompanied by a switch from glycolysis to aerobic oxidation. Like its upstream NAMPT, SIRT1 also plays a key role in metabolic reprogramming. More importantly, the results in this study indicate that NF-κB activation, a key step in M1 polarization, is also controlled by SIRT1. Therefore, it is reasonable to believe that SIRT1 is an important downstream target of α7nAChR and an important way for CAP to interfere with innate immunity. These findings suggest that the restoration of immune homeostasis under MG treatments could be the foundation for the overall therapeutic effects on experimental arthritis.

Conclusion

This study revealed that the intervention of MG on CAP is the basis of SIRT1 up-regulation, and consequently down-regulated NF-κB pathway in macrophages and M1 polarization. On this basis, it was preliminarily elucidated the mechanism of MG intervention in macrophage polarization treatment of early AIA rats to improve the prognosis of the disease. In summary, we have proved that MG stimulates the CAP-SIRT1 pathway and improves the peripheral immune environment, thereby inhibiting the polarization of M1 through the NF-κB pathway and improving the pathological immune environment of early AIA rats.